Compare · BBLG vs STE
BBLG vs STE
Side-by-side comparison of Bone Biologics Corp (BBLG) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBLG and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $20.50B, about 9134.9x BBLG ($2.2M).
- Over the past year, BBLG is down 72.5% and STE is down 13.5% - STE leads by 59.0 points.
- STE has been more active in the news (39 items in the past 4 weeks vs 1 for BBLG).
- STE has more recent analyst coverage (16 ratings vs 0 for BBLG).
- Company
- Bone Biologics Corp
- STERIS plc (Ireland)
- Price
- $1.24-2.36%
- $210.04-1.01%
- Market cap
- $2.2M
- $20.50B
- 1M return
- -7.46%
- -1.87%
- 1Y return
- -72.52%
- -13.48%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 39
- Recent ratings
- 0
- 16
Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest BBLG
- Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
- SEC Form 10-Q filed by Bone Biologics Corp
- Bone Biologics Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Bone Biologics Corp
- SEC Form 10-K filed by Bone Biologics Corp
- SEC Form 4 filed by Chief Financial Officer Walsh Deina H
- SEC Form 4 filed by Chief Executive Officer Frelick Jeff
- Bone Biologics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
- Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
Latest STE
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 401 units of Ordinary Shares, decreasing direct ownership by 1% to 36,678 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 65 units of Ordinary Shares, decreasing direct ownership by 1% to 6,194 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 195 units of Ordinary Shares, decreasing direct ownership by 2% to 12,257 units (SEC Form 4)
- SVP & GM, AST Kohler Kenneth E covered exercise/tax liability with 150 units of Ordinary Shares, decreasing direct ownership by 1% to 11,332 units (SEC Form 4)
- SVP & Chief HRO Fraser Mary Clare covered exercise/tax liability with 600 units of Ordinary Shares, decreasing direct ownership by 4% to 13,716 units (SEC Form 4)
- President and CEO Carestio Daniel A covered exercise/tax liability with 1,889 units of Ordinary Shares and sold $946,799 worth of Ordinary Shares (4,428 units at $213.82), decreasing direct ownership by 9% to 63,647 units (SEC Form 4)
- Sr. Vice Pres., CFO Burton Karen L covered exercise/tax liability with 90 units of Ordinary Shares, decreasing direct ownership by 0.68% to 13,184 units (SEC Form 4)
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 365 units of Ordinary Shares, decreasing direct ownership by 0.97% to 37,079 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 64 units of Ordinary Shares, decreasing direct ownership by 1% to 6,259 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 239 units of Ordinary Shares, decreasing direct ownership by 2% to 12,452 units (SEC Form 4)